DiscGenics has gained acceptance from the U.S. FDA for the clinical protocols and Chemistry, Manufacturing, and Controls (CMC) clinical development plan for Phase III clinical program of its allogeneic, injectable disc progenitor cell therapy (IDCT or rebonuputemcel) for painful lumbar degenerative disc disease (DDD), allowing the study to proceed.

The International Journal of Spine Surgery publishes results from the combined Phase I/Phase II, first-in-human clinical study of an allogeneic disc progenitor cell therapy (IDCT or rebonuputemcel) for painful lumbar degenerative disc disease.

DiscGenics CEO and Chairman, Flagg Flanagan will present at Canaccord Genuity 2024 Musculoskeletal Conference taking place in San Francisco on Monday, February 12, 2024.

DiscGenics has announced a basic science Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) to assess the feasibility of using DiscGenics’ proprietary Discogenic Cells with the VA’s whole, tissue-engineered endplate-modified disc-like angle ply structure (eDAPS).

DiscGenics CEO and Chairman, Flagg Flanagan will present at Canaccord Genuity’s 18th Annual Musculoskeletal Conference taking place in Las Vegas, NV on Tuesday, March 7, 2023.

Discogenic progenitor cell therapy safely increased disc volume and provided rapid, durable improvements in low back pain, function, quality of life, and pain medication usage out to two years post-injection in patients with lumbar DDD.

DiscGenics Chief Executive Officer and Chairman Flagg Flanagan will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:30 p.m. PST.

IDCT was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months.

DiscGenics Chief Executive Officer and Chairman Flagg Flanagan will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:00 a.m. EST.

Goldman Sachs (NYSE:GS) has recognized DiscGenics Chairman and CEO Flagg Flanagan as one of the 100 Most Intriguing Entrepreneurs of 2021.

DiscGenics has enrolled a total of 38 subjects in its Japanese clinical study of IDCT. Meanwhile in the U.S., all currently enrolled trial subjects have completed their one-year study visits.

An independent data safety monitoring committee (DSMC) has given DiscGenics the go-ahead to enroll the final 24 patients in its first-in-human U.S. clinical study of IDCT.

DiscGenics Chairman and CEO Flagg Flanagan will present at the 2019 Musculoskeletal New Ventures Conference on Tuesday, October 29, 2019 in Memphis, TN.

The first 30 subjects have been safely treated DiscGenics’ first-in-human U.S. clinical study of IDCT, an allogeneic, injectable disc cell therapy for mild to moderate degenerative disc disease (DDD).

The first patients have been treated in DiscGenics’ Japanese safety study, a clinical trial of IDCT for mild to moderate degenerative disc disease in Japan.

Chief Medical Officer, Kevin T. Foley, MD, FACS, FAANS was awarded the 2019 AANS Cushing Award for Technical Excellence and Innovation in Neurosurgery. The award honors an AANS member for technical prowess and skill and/or innovation in the development of new procedures that have become part of the arsenal a neurosurgeon uses to treat disease or trauma.

DiscGenics is expanding operations in Salt Lake City with an approximately 25,000 sq. ft. space where it intends to build a research and development facility along with manufacturing operations.